Everest_Medicines licenses Sumecigrel in Asia-Pacific
Analysis based on 7 articles · First reported Jun 09, 2026 · Last updated Jun 11, 2026
The licensing agreement between Everest Medicines>>> and Jiangsu Vcare PharmaTech>>> for Sumecigrel>>> is expected to positively impact the stock price of Everest Medicines>>> due to the expansion of its cardiovascular portfolio and market presence in the MSCI Asia Pacific Index region. This collaboration also signals potential for significant revenue generation from a 'Best-in-Class' product in the antithrombotic market, benefiting both companies.
Everest Medicines>>> has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech>>> for the development, registration, and commercialization of Sumecigrel>>> across the MSCI Asia Pacific Index region. This agreement involves an upfront payment of RMB 20 million from Everest Medicines>>> to Jiangsu Vcare PharmaTech>>>, along with future milestone payments and commercial supply procurement. Sumecigrel>>> is a next-generation oral P2Y12 receptor antagonist, clinically developed for the treatment and prevention of atherothrombotic events like acute coronary syndrome, ischemic stroke, and peripheral arterial disease. It has completed Phase I, Phase II, China-US PK/PD bridging study, and Phase III clinical trials, demonstrating favorable efficacy and safety. This collaboration strengthens Everest Medicines>>>' cardiovascular portfolio and its strategic focus on the MSCI Asia Pacific Index market, while for Jiangsu Vcare PharmaTech>>>, it represents the first step in Sumecigrel>>>'s global commercialization strategy.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard